Lightnews — Scholar-powered news

Yan Leyfman, MD

@yleyfman.bsky.social

1.1K followers 650 following 560 posts

nyti.ms

Posts Media Videos Starter Packs

Pinned

Yan Leyfman, MD @yleyfman.bsky.social · Nov 12

What sets MedNews Week apart? What are some exciting future initiatives?

Check out our latest feature for an exclusive behind-the-scenes look at the impact we're aiming to make with our unique partnership with Global Education Leader OncLive!

www.onclive.com/view/park-an...

Park and Leyfman Hope to Advance Mission of MedNews Week Through Collaboration With OncLive

Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.

www.onclive.com

1 1 9

Yan Leyfman, MD @yleyfman.bsky.social · 17d

Thank you for your support

Reposted by Yan Leyfman, MD

OncoDaily @oncodaily.bsky.social · 17d

Honored to Join the Advisory Board of CancerNetwork - Yan Leyfman

@yleyfman.bsky.social

oncodaily.com/career/advis...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork

Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork - OncoDaily

Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork / cancer, CancerNetwork, OncoDaily, Oncology, ONCOLOGY/CancerNetwork, Yan Leyfman

oncodaily.com

1 1 4

Yan Leyfman, MD @yleyfman.bsky.social · 18d

I’m energized to help grow this rising research journal, drive forward novel science, and translate the latest breakthroughs into better care for clinicians and patients around the world. 🔬🩺

Excited to contribute, learn, and collaborate. 🌍

Yan Leyfman, MD @yleyfman.bsky.social · 18d

I’m deeply honored to join the Advisory Board of ONCOLOGY / CancerNetwork. 🎉 Thank you to Ariana Pelosci & the editorial team for this invitation — I’m grateful for the opportunity to work alongside such an esteemed group of clinical and scientific leaders. 🙏

1 2

Yan Leyfman, MD @yleyfman.bsky.social · 18d

Thank you for your support

Yan Leyfman, MD @yleyfman.bsky.social · 21d

Thank you for your support.

Yan Leyfman, MD @yleyfman.bsky.social · 22d

Thank you for your support.

Yan Leyfman, MD @yleyfman.bsky.social · Sep 3

Stories like these remind us that behind every healthcare career lies a deeply personal “why.”

💭 What’s yours?

🎧 Listen to the full interview here: pod.link/1823798473/e...

#chernobyl #physician #medicine #healthcare #humanity

pod.link

Yan Leyfman, MD @yleyfman.bsky.social · Sep 3

Grateful to the Humanity Rx Podcast for highlighting my story, my passion for oncology & my commitment to advancing patient care & research innovation.

As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.

pod.link

Reposted by Yan Leyfman, MD

OncoDaily @oncodaily.bsky.social · Aug 10

Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL

@yleyfman.bsky.social @bristolmyerssquibb.bsky.social

oncodaily.com/voices/yan-l...

#Cancer #Oncology #OncoDaily #Health #Medicine

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - OncoDaily

Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL / Bristol Myers Squibb, cancer, FDA,

oncodaily.com

1 6

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

#WomenInLymphoma #VoicesInLymphoma #HemeOnc #OncologyMentorship #WomenInMedicine #CareerDevelopment #GlobalOncology #LymphomaLeadership #MentorshipMatters #MedTwitter #AcademicMedicine #LymphomaCare #OncLive #MedNewsWeek @womeninlymphoma.bsky.social @onclive.bsky.social

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

📲 Register today! globalmeet.webcasts.com/starthere.js...

Career Development & Mentorship in Medicine - 1728791

globalmeet.webcasts.com

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

👩‍⚕️ Dr. Judith Trotman

Director, Clinical Research Unit, Concord Repatriation General Hospital, Sydney, Australia

Whether you're a trainee, early-career physician, or seasoned clinician, this session will offer inspiration and actionable advice.

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

👩‍⚕️ Dr. Ann LaCasce

Director, Fellowship Program, Dana-Farber/Mass General Brigham

Associate Professor, Harvard Medical School

Career Development & Mentorship in Medicine - 1728791

globalmeet.webcasts.com

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

Join us for a powerful conversation with two world-renowned leaders in hematology-oncology as they share their journeys, challenges, and insights on mentorship, career growth, and shaping the future of lymphoma care.

Yan Leyfman, MD @yleyfman.bsky.social · Aug 6

🎥 MedNews Week x OncLive x Women in Lymphoma Present:

🌟 Voices in Lymphoma: Women Shaping Care 🌟

Career Development & Mentorship in Medicine

🗓️ Tuesday, August 12

⏰ 6:30 PM EST

1 1 2

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

#MultipleMyeloma #CAR_T #Talquetamab #RRMM #Oncology #Hematology #CellTherapy #RealWorldEvidence #MyelomaResearch #Immunotherapy #GPRC5D #BCMA

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

Evidence of sustained CAR-T expansion around day 14

💡 Conclusion:

Talquetamab is emerging as a promising bridging option to BCMA CAR-T, particularly for high-risk, trial-ineligible patients who are otherwise vulnerable to disease progression during CAR-T manufacturing.

1 1

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

Toxicity profile: no grade ≥3 CRS, 2% grade 3 ICANS; common but manageable talquetamab-related side effects (oral 70%, skin 38%, nails 17%)

🧠 CAR-T Outcomes Post-Bridging:

88% overall response rate (54% complete response)

Minimal grade ≥3 toxicity post-infusion

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

🧬 Bridging Outcomes:

71% response rate to talquetamab

119/134 patients proceeded to CAR-T (98 cilta-cel, 21 ide-cel)

Median talquetamab duration: 23 days

Most received 0.8 mg/kg biweekly

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

👥 Patient Cohort (n=134):

Median age: 65

Median prior therapies: 5

44% with high-risk cytogenetics

41% with extramedullary disease

85% ineligible for CARTITUDE-1/KarMMa trials

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

📊 Study Overview:

A multi-institutional retrospective analysis (20 centers: 18 US, 2 Germany) evaluated talquetamab, a GPRC5D-targeting bispecific antibody, as bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma (RRMM).

1 1

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

It allowed transition to BCMA CAR-T (cilta-cel or ide-cel) in heavily pretreated, high-risk patients, including many who would not have qualified for clinical trials.

1 1

Yan Leyfman, MD @yleyfman.bsky.social · Aug 2

🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄

📌 Key Takeaways:

Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.

Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy

Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition

ashpublications.org

1 2

Yan Leyfman, MD @yleyfman.bsky.social · Aug 1

Thank you